18 results about "Haemorrhagic disorders" patented technology

The invention relates to the field of biological medicines, in particular to application of an SR604 injection to preparation of a medicine for preventing and / or treating hemorrhagic diseases. The SR604 injection provided by the invention contains an SR604 antibody, and the injection dosage of the SR604 antibody in the SR604 injection is selected from 0.025 mg / kg to 0.8 mg / kg. The injection provided by the invention can be used for preventing and / or treating hemorrhagic diseases, the number of hemorrhagic events and the annual hemorrhagic rate of a patient are remarkably reduced by controlling the injection dosage and the injection frequency, and the injection has a relatively good treatment effect on hemophilia A, hemophilia B and congenital blood coagulation factor VII deficiency.

The present invention relates to single domain antibodies (sdAbs) against TREM (triggering receptors expressed on myeloid cells) like transcript-1 (TLT-1) molecules that are present on activated platelets at the site of an injury, and especially on a subset of activated platelets, coated platelets. Furthermore, the present invention relates to fusion proteins comprising sdAbs against TLT-1 and an extracellular (soluble) domain of tissue factor (sTF), to direct targeting of such fusion proteins to activated platelets at the site of injury through binding of the sdAbs to TLT-1, a membrane protein receptor that is only present on activated platelets. Specific interaction of sdAbs with the TLT-1 receptor positions the sTF domain of the fusion to interact with, and activate, FVII. As a result, a targeted procoagulant effect is achieved at the site of injury via activated platelets. The fusion proteins are useful to treat individuals that have a bleeding disorder, such as hemophilia A, hemophilia B, or acute bleeding due to traumatic injury.

An organic sol-gel nano-composition containing three solid lipid nano-components loaded with phytochemical active ingredients is proposed. Panax notoginseng saponins are extracted from Vietnamese Panax notoginseng. Rutin is extracted from Styphnolobium japonicum in Thai Binh Province, Vietnam, and Ginkgo biloba is extracted from Ginkgo biloba trees. The composition has shown to have low toxicity and great bioavailability. In particular, the composition is effective against local myocardial ischemias and arrhythmias, improves the blood rheology, platelet circulation and antiaggregation, and thrombosis, lowers the blood lipids to a certain limit, and has good effects against atherosclerosis. The composition has an antioxidant effect of preventing free radical damages, and has an effect of enhancing capillary resistance, strengthening the vessel walls that reduces hypertension risks, which accordingly protects the cerebral nerves, prevents strokes, and is also used to recover after strokes and other hemorrhagic diseases for the enhancement effects and reconstruction of the damaged blood vessels.

Various embodiments of the invention utilize chalcones to treat blood, bleeding, and / or bleeding disorders. As described herein, chalcones significantly reduce blood clotting time in normal / hemophilic blood and normal / hemophilic animal models. As also described herein, chalcones reduce blood clotting time and increase blood clotting efficiency without any apparent risk of immunogenicity or unwanted blood clots. As also described herein, chalcones reduce the inhibitory activity of antithrombin on thrombin-driven blood clotting, thereby increasing the effectiveness of the thrombin mechanism in clotting blood.

Devices and methods for reducing or limiting bleeding in an animal by stimulating the spleen with focused ultrasound (FUS). The devices and methods can be used to treat blood disorders such as hemophilia, or to reduce bleeding during surgery or due to trauma. The methods can be administered to a patient non-invasively by applying ultrasound energy transcutaneously.

Provided are the compositions (e.g., pharmaceutical compositions) of coagulation factor X activator (FX activator, e.g., RVV-X) comprising sucrose, histidine, polysorbate 20, and mannitol, and uses of FX activators (e.g., RVV-X) or compositions (e.g., pharmaceutical compositions) thereof for treating a bleeding disorder (e.g., hemophilia) in an individual (e.g., human).

Aspects of the present disclosure are directed to a gene therapy approach for treating bleeding disorders, in particular Haemophilia comprising transduction of autologous hematopoietic stem and progenitor cells (HSPCs) with lentiviral viral vectors for expression of blood clotting factors to correct their deficiency in these disorders. The invention further discloses a process and formulation comprising transduced cells for the administration to patients, preferably with bleeding disorders, in particular preceded by a conditioning regimen.The disclosure also describes myeloablative, non-myeloablative or non-genotoxic conditioning regimens, for preparing the patient for transplantation with formulation of the invention.

This invention provides a method for treating patients with bleeding disorders such as hemophilia. [Solution] The present invention relates to an iRNA, such as a double-stranded ribonucleic acid (dsRNA), composition that targets the Serpinc1 gene, and to a method of using such an iRNA, such as a dsRNA, composition to inhibit the expression of Serpinc1 and to treat subjects with Serpinc1-related diseases, such as bleeding disorders such as hemophilia.

1. The name of the design product: full-automatic platelet aggregometer (RealG-PF3 Pro). 2. The use of the design product: a medical testing device for monitoring the efficacy of anti-platelet drugs, identifying and diagnosing bleeding diseases, and monitoring thrombotic diseases. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

Apparatuses and methods for reducing or limiting bleeding in an animal by focused ultrasound (FUS) stimulation of the spleen. The apparatuses and methods may be used treat blood disorders such as hemophilia, or to reduce hemorrhage in surgery or due to traumatic injury. The methods may be non-invasively administered to the patient by transcutaneous application of ultrasound energy.

The present disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a miRNA and / or a therapeutic protein. In certain embodiments, the therapeutic protein comprises a clotting factor, e.g., a FVIII polypeptide, a FIX polypeptide, or a fragment thereof. In some embodiments, the first ITR and / or the second ITR is an ITR of a non-adeno-associated virus (AAV). The present disclosure also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject the nucleic acid molecule or a polypeptide encoded thereby.

The invention discloses a catheter rehemorrhagic disease and vascular occlusion interventional therapy device integrated with pressure sensing, and belongs to the technical field of vascular interventional therapy, and the catheter rehemorrhagic disease and vascular occlusion interventional therapy device integrated with pressure sensing comprises a pressure pump for controlling pressure, a pressure output port of the pressure pump is in through connection with a stamping pipe through a hose, the other port of the stamping pipe is in through connection with a catheter, a guide wire is in through connection in the catheter in the central axis direction, the end, away from the stamping pipe, of the catheter is sleeved with a balloon, and a liquid outlet is formed in the area, located in the balloon, of the catheter. Embedded circular grooves are symmetrically formed in the positions, located on the two sides of the balloon, of the outer portion of the catheter, and pressure sensors are installed in the embedded circular grooves in an embedded mode; the vascular treatment intervention device can drive the pressure sensor to move and be attached to the inner wall of a blood vessel when the balloon is controlled to expand to block the blood vessel, so that the pressure change is accurately measured, and the blocking treatment effect is improved.

Various embodiments of the invention utilize chalcones to treat blood, bleeding, and / or bleeding disorders. As described herein, chalcones significantly reduce blood clotting time in normal / hemophilic blood and normal / hemophilic animal models. As also described herein, chalcones reduce blood clotting time and increase blood clotting efficiency without any apparent risk of immunogenicity or unwanted blood clots. As also described herein, chalcones reduce the inhibitory activity of antithrombin on thrombin-driven blood clotting, thereby increasing the effectiveness of the thrombin mechanism in clotting blood.

Via yeast display technology, albumin binding variants were selected, and variants displayed improved binding to MSA or both HSA & MSA. All variants were subcloned into the pHEN-expression plasmid and expressed in E coli WK6 cells. Purified nanobodies were then analyzed for their capacity to bind immobilized MSA. Biotinylated nanobodies were then tested in vivo for their circulatory half-life. They then validated the effect of their nanobodies anti albumin linked with another nanobodies such as single-domain antibody anti-D′D3 as described in WO2017129630 and WO2018091621.Mice having reduced levels of VWF (Von Willebrand disease type-1) received a single dose of the bispecific single-domain antibody. VWF and FVIII levels were followed over 14 days. These data show that there is a statistically significant increase in VWF and FVIII levels, which is maintained for 10 days.The present invention relates to an isolated single-domain antibody (sdAb) directed against albumin and its uses in different diseases such as bleeding disorders.

Provided are a novel coagulation factor X activating enzyme, a pharmaceutical composition comprising same, and use thereof in preparing a medicament for treating hemorrhage or hemorrhagic diseases. Also provided is a method for purifying a coagulation factor X activating enzyme, which adopts a sequential combination of anion exchange chromatography and cation exchange chromatography, has higher yield while ensuring the high purity and high activity of the product, greatly improves the cost-efficiency, and is beneficial to large-scale industrial production.

The invention relates to application of a cytoskeleton regulator in preparation of a blood coagulation promoting drug, and belongs to the technical field of biological medicines, and the blood coagulation promoting drug is a drug for treating or preventing hemorrhagic diseases related to low blood coagulation function. The hemorrhagic diseases comprise traumatic hemorrhage, surgical operation related hemorrhage, hepatopathy related hemorrhage, postpartum hemorrhage, hemophilia, hemorrhage caused by excessive anticoagulant drugs, thrombocytopenia or dysfunction related hemorrhage; the cytoskeleton regulator is one or more of a compound for inhibiting polymerization of actin microfilaments, a compound for inhibiting shrinkage of myosin and a ROCK kinase inhibitor; the cytoskeleton regulator can be used for preparing a procoagulant treatment drug, the effect is played by inducing endogenous cells of a body to release procoagulant particles, a brand new strategy is provided for a clinical hemostatic drug, and the cytoskeleton regulator can remarkably shorten the coagulation time of whole blood; the bleeding time can be remarkably shortened, the total blood loss amount is reduced, and the powerful in-vivo bleeding stopping effect is achieved.